AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Pending Claims by Quarter
Pending Claims — International Product Liability Lawsuits (cases)
AbbVie Pending Claims: 1,080 in Q2 2026, up 7.5% from a year earlier. That is the highest of the 9 quarters on record here.
Latest, Q2 2026
1,080
Period ended Jun 30, 2026
Change on a year earlier
+7.5%
1,005 in Q2 2025
History
9 quarters
Since Q2 2024
Sources
9
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-03) ↗
Reported in Form 10-Q / 10-K Contingencies Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pending Claims — International Product Liability Lawsuits (cases) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,080 | +7.5% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,080 | +8.0% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,080 | +8.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,025 | +28.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,005 | +25.6% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,000 | – | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,000 | – | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 800 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 800 | – | Form 10-Q (filed 2024-08-07) ↗ |
Cite this data
StockData. (2026). AbbVie Pending Claims, quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit-prod-intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.